Psychological Morbidity and Facial Volume in HIV Lipodystrophy: Quantification of Treatment Outcome

NHS Lothian

Status: Completed

Conditions: HIV-Associated Lipodystrophy Syndrome

Study type: Observational

Funder types: Other

Identifiers

NCT01359917

REC06/MRE00/39

Details and patient eligibility

About

The hypotheses of this study were that:

1. HIV lipodystrophy is associated with psychological morbidity relating to body image, anxiety and depression.
2. Treatment of HIV lipodystrophy using autologous fat transfer, polylactic acid or Bio-alcamid, is associated with an improvement in psychological morbidity and anatomical volume of treated areas.
3. The DI3D system is a valid and reproducible method of recording and measuring facial 3-D volume.

Full description

as above

Enrollment: 50 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• HIV facial lipoatrophy
• concurrent antiretrovirals

Exclusion criteria

• known psychological disorder
• skin allergies
• significant medical problems precluding anaesthesia

Trial design

50 participants in 3 patient groups

autologous fat transfer

Description:

patients received fat transfer for HIV lipodystrophy

polylactic acid

Description:

treatment with polylactic acid (PLA) for HIV lipodystrophy

bio-alcamid

Description:

bio-alcamid injections